CTCX

About Carmell Therapeutics Corporation

Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.

CEO: Rajiv Sarman Shukla
IPO Date: Sep 23, 2021

Market Data

Open: $0.199
High: $0.2074
Low: $0.188
Volume: 63.4K
Avg Volume: 8.1M
52W High: $3.00
52W Low: $0.1701

Valuation

Market Cap: $5.9M
Enterprise Value: $506k
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-3.3M
Revenue: $1.9M
Net Income: $-6.9M
Cash: $707k
Debt: $310k

Events

EarningsMay 15

actual -0.07203